Daily aspirin associated with a reduced risk of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: a population-based cohort study

Lee, Teng-YuTeng-YuLeeHsu, Yao-ChunYao-ChunHsuHo, Hsiu JHsiu JHoJAW-TOWN LINChen, Yi-JuYi-JuChenWu, Chun-YingChun-YingWu2023-10-252023-10-252023-0725895370https://pubmed.ncbi.nlm.nih.gov/37434747/https://scholars.lib.ntu.edu.tw/handle/123456789/636503Emerging laboratory and animal studies suggest that aspirin may prevent non-alcoholic fatty liver disease (NAFLD)-related hepatocellular carcinoma (HCC), however clinical evidence remains lacking.enAntiplatelet; Chemoprevention; Liver cancer; PreventionDaily aspirin associated with a reduced risk of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: a population-based cohort studyjournal article10.1016/j.eclinm.2023.102065374347472-s2.0-85163552830https://api.elsevier.com/content/abstract/scopus_id/85163552830